OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-03-31-accounts

REGISTERED COMPANY NUMBER: 02143917 (England and Wales) REGISTERED CHARITY NUMBER : 327493

Trustees' Report and

Audited Financial Statements for the Year Ended 31 March 2024

for

CHILDHOOD EYE CANCER TRUST

(A COMPANY LIMITED BY GUARANTEE)

Knox Cropper LLP Chartered Accountants and Statutory Auditors 65 Leadenhall Street

London EC3A2AD

CHILDHOOD EYE CANCER TRUST

Contents of the Financial Statements for the Year Ended 31 March 2024

----- Start of picture text -----
Page
Reference and Administrative Details 1
Trustees Report 2 - 21
Report of the Independent Auditors 22 - 24
Statement of Financial Activities 25
Balance Sheet 26
Cash Flow Statement 27
Notes to the Financial Statements 28 - 39
----- End of picture text -----

CHILDHOOD EYE CANCER TRUST

Reference and Administrative Details for the Year Ended 31 March 2024

TRUSTEES

Ian Ellington - Chairman Gemma Boggs - Treasurer Lisa Brown (resigned 24.06.24) Elizabeth Coleman Alex Brebbia Andrea Bonzano Matthew Holt Rob Downes Damian Yeo Michelle Boothroyd Anya Ward (appointed 01.09.23) Patrick Tonks (appointed 19.12.23)

COMPANY SECRETARY

Rose-Marie Sexton

REGISTERED OFFICE

The Royal London Hospital, Whitechapel Road, London, E11BB

REGISTERED COMPANY NUMBER

02143917 (England and Wales)

REGISTERED CHARITY NUMBER

327493

INDEPENDENT AUDITORS

Knox Cropper LLP, Chartered Accountants and Statutory Auditors, 65 Leadenhall Street, London, EC3A2AD

Page 1

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

Report of the Trustees for the Year Ended 31 March 2024

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Page 2

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

OBJECTIVES AND ACTIVITIES

Objects of the Charity

The Objects of the Charity are to promote the relief of children with Retinoblastoma and to provide ongoing support for those affected.

This means the Childhood Eye Cancer Trust is dedicated to helping anyone affected by retinoblastoma (Rb), a type of eye cancer that affects babies and young children, mainly under the age of six. We have been supporting families since 1987.

Around one child a week is diagnosed with Rb in the UK or 50 a year. It accounts for 3% of childhood cancers in the UK and 10% of cancers in babies under one. Around 45% of cases are heritable and this carries with it an increased risk of developing tumours in other parts of the body in later life.

The Charity was originally founded to provide support and information to those affected by Rb. In 1994 we merged with another charity that was funding research projects specifically related to Rb, and in 2004 we changed our name to the Childhood Eye Cancer Trust. As we grew, so did our aims and objectives and we began to run campaigns aimed at raising awareness among health professionals and the public in order to achieve the earliest possible diagnosis for children affected.

Our aims are to:

Objectives, Strategies for Achievement and Public Benefit

During the period of this report, we have continued to deliver against our three core goals of support, research, and awareness.

The Trustees annually review the core goals and have reaffirmed that these remain the charitable focus.

The Trustees are aware of the public benefit guidance published by the Charity Commission. We have considered the objectives of the Charity and have given regard to how these objectives and the associated activities meet the public benefit criteria of advancing health, saving lives and the relief of those in need by reason of ill health.

We are the only UK-wide charity providing support to people affected by Rb and we believe that they benefit from our services in the following ways:

Main Objectives

Support: To ensure that everyone affected by Rb in the UK has access to support and information according to their need.

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

days, support is provided via telephone, video call, email, and social media.

Our team provides signposting to organisations for financial grants, benefits advice, therapeutic and psychological support, visual impairment support, holidays, travel expenses, white goods, and other items.

Allowance, as well as supporting families with housing applications.

The support team collaborates with the wider CHECT team with stories from members for CHECT publications, information leaflets and social media.

Awareness - healthcare professionals: To save lives and minimise the impact of visual impairment by ensuring healthcare professionals a r e a w a r e a n d know about Rb and its symptoms, listen to concerned parents and make urgent referrals where necessary.

Awareness - public: To increase awareness of Rb and its signs and symptoms amongst parents, guardians and carers to promote the seeking of medical advice as soon as possible.

Research: Proactively engaging in the advancement of knowledge of Rb, its treatment and its impact.

Influencing: Working with other organisations to bring about improvements in the way in which services are funded and delivered in the UK.

Page 4

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

Research Grant Making: We award grants to groups or individuals who wish to pursue research projects or audits to advance knowledge of Rb and related issues.

Applications go before the Scientific Advisory Committee which is made up of CHECT Trustee(s) and Chief Executive plus experts from research and Rb-related fields. We also have three lay members representing families and the adult Rb community within the SAC.

The committee evaluates the validity and appropriateness of the proposals using an agreed scoring matrix, seeking expert review for large projects and where necessary for other reasons, before making recommendations to the Board for funding.

Grant recipients are required to provide six-monthly progress reports and present a final report to the SAC and Board on the conclusion of the project before disseminating the findings and learning through presentations and publications.

Volunteers

26 volunteers (including Trustees and SAC members) generously gave their time to support us throughout the year.

Whether it was one off or ongoing support, we would like to thank each and every one of our volunteers for their invaluable contribution to our work.

Page 5

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

ACHIEVEMENT AND PERFORMANCE

Charitable activities

Support

Whilst one of our core priorities is the delivery of support to the parents and carers of children affected by Rb, we have extended this to encompass anyone affected, including teenagers whose unique needs are very different to those of a young child or baby, and adults, many of whom are living with the late effects of the treatment they received for Rb as a child. Membership of CHECT is open to anyone affected by retinoblastoma (as well as their friends and family), supporters of CHECT and health professionals. We do not charge a membership fee.

In 2023/24, 100% of families were offered support following a diagnosis of Rb in the UK. As well as face to face, email, and telephone, we continue to use virtual platforms to support our members.

There has been an increase in the number of face-to-face sessions delivered with over 1,300 sessions delivered across both treatment hospitals at inpatient and outpatient clinics.

We record and monitor support interactions so that we ensure the service is meeting the needs of those affected by Rb as best it can.

Face to face and remote support

The main areas that people sought support from CHECT in 2023/24 included:

*There is an increasing number of families with housing concerns and homelessness, including a rise in the numbers of those coming from abroad to seek treatment for their child. This often requires enhanced levels of support.

We also continue to receive a small number of enquiries from non-members. These mainly consist of international patients requesting advice as well as UK based parents, guardians or carers who have symptom concerns in their child.

Social media support

Social Media is a vital source of support resources and information, with both members and non-members contacting us. We also raise awareness utilising all social media channels, including Facebook, Instagram, X, LinkedIn and TikTok. As well as our main public-facing Facebook page, we have two closed groups for members which are for parents of children with Rb and adults who have had Rb, both of which have seen increases in membership in the period.

Financial Support

In 2023/24 we provided 63 CHECT support grants totaling £10,250 to families and individuals to help with the costs associated with an Rb diagnosis and ongoing treatment - for example travel to and from hospital as well as occasionally helping to buy some specialist equipment for those with a visual impairment.

Page 6

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

The demand for support grants continues to increase in line with the cost-of-living crisis and our team continues to work in partnership with other organisations to offer as much financial support as possible.

Community Cost of Living Fund. This allowed us to offer further emergency grants in the form of supermarket vouchers to member families who were in need. A total of 52 families received vouchers in March 2024.

Support Events

In 2023/24, we organised 5 face-to-face support events:

Hospital organised events were also attended by our support team.

The support service also delivered 7 online events:

These virtual events provided opportunities for peer-to-peer support.

Pip the Penguin

Pip (our enucleation support toy) continues to be very popular with 98 given to affected children. This support tool is used as a support tool for families and clinicians to normalise and explain the enucleation process.

Teenage and Young Adult (TYA) Support

TYA who had Rb as children can face specific challenges around self-esteem. We provide specialist support to meet need and facilitate invaluable peer support.

We have a specific website and Instagram channel for TYAs, where they can contribute stories and information appropriate to their audience.

Adults (Beyond Rb)

For some people, the effects of Rb are lifelong. We continue to respond to the needs of adults who were affected by Rb as children.

We have a specific Beyond Rb group, the membership of which has grown via Facebook into a dedicated WhatsApp Group.

Partnerships

Collaboration and partnership development is a vital activity in the enhancement of our support provision.

Both support workers work very closely with the Guide Dogs Eye Clinic Liaison Officers (ECLOs) based in each specialist centre and who offer advice, information and resources for children living with a visual impairment.

Ongoing partnership continues with immense gratitude via organisations such as Family Fund, Young Lives vs Cancer, the Free Kicks Foundation, and the Gavin Glynn Foundation. We continue to offer

Page 7

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

activities to children and young people indirectly through partners such as Barretstown, the Ellen MacArthur Trust, and VICTA.

New partnerships have enhanced support for people affected by Rb and include wish organisation Molly Ollys; and Box4Kids who gift our members experiences and free events tickets.

Feedback From Those Supported

working, this voucher (given to us via CHECT) will really make a difference in helping me provide for my little one. It will go a long way in ensuring we have enough for food, milk, and nappies. Your thoughtfulness and generosity are truly appreciated, and I am grateful to be a recipient of your support. Thank you once again for your kindness and for making a positive impact in our lives

"We were put through to the Childhood Eye Cancer Trust on the day that we had the diagnosis, and their support worker was allocated to us

"CHECT have always been there, calling or texting me. Our support worker has been great and always offered her support and checked in every time we have been at Royal London Hospital through the good to work, she has helped me with contacting charities for financial support. CHECT are great and cannot recommend enough."

"Our support worker from CHECT is always so lovely and supportive in the clinic. She makes sure that she spends time with each family to see if there is anything they need and any way that CHECT can help. She put us in touch with a charity that provided a tablet for our daughter to watch her favourite programs on when she has to attend clinic appointments, which has been great. I know that if I needed any advice or

remember at the start when we found out about our daughter having cancer it was hard to process and we were overwhelmed, but it was good to know that CHECT is there, and we can contact them whenever we need to. They kept checking how we are doing mentally and financially, letting us know we are not alone in this situation. Reading other people's stories who went through retinoblastoma on the CHECT website was also helpful to have a better understanding of what we may go through and relate to some scenarios. Our support worker from CHECT is such a friendly, cheerful, and kind person, she kept in touch asking how we

Awareness

Rb is a rare disease which means that most people are not aware of it. Sadly, this frequently leads to a delay in a diagnosis being made and, because Rb is a fast-growing cancer, quick access to treatment can be vital in order to save a child's eyes, sight and life.

Raising awareness of Rb among both healthcare professionals and the public is therefore important in helping to drive early diagnosis and as such remains a key part of our work.

Pathways to Diagnosis

In 2012, as part of its aim to reduce the delays in diagnosis of retinoblastoma experienced by some families in the UK CHECT began to collect information from parents called 'Pathways to Diagnosis'.

This information is gathered by support workers during the course of their conversations with families, and

Page 8

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

focused on whether the families had any prior awareness of retinoblastoma; the signs they noticed in their child's eyes that prompted them to seek help; and the actions taken by the healthcare professionals they consulted.

It is apparent that the range of experience is huge: from families who were referred to one of the two specialist Rb centres in the UK within days of noticing their child's symptoms; to families who spent over six months and numerous visits to various healthcare professionals before anyone recognised the significance of what they were reporting or carried out the appropriate tests and made appropriate referrals.

Recording these experiences in a quantitative way allowed CHECT to refine messages and information to address those areas where it was most needed: not only to alert parents of young children, but also GPs, health visitors and opticians to the main signs and symptoms of Rb, and the need for urgent examination and onward referral.

In 2023 the total number of pathways collected was 33.

Unusually, this year less parents took their child to the GP in the first instance on noticing something unusual with their eyes than any year since this study started in 2012. And more than in any other year, they took their child to an optician in the first instance.

This may be either because families are struggling to get an appointment with their GP, or because GP positive for those families concerned, as opticians have a much better track record at making appropriate referrals for children with retinoblastoma than GPs (69% vs 45% from 2014 2023).

Encouragingly, this year saw more children than ever, since 2012, following the appropriate referral route. 67% of children received urgent referrals after their first consultation with a healthcare professional to their local ophthalmology department (and then onto one of the specialist Rb centres). This is compared to the eleven-year average of 44%.

Unsurprisingly, this was reflected in the overall speed of referrals. 2012 to 2022 shows that 22% of children were diagnosed at one of the specialist Rb centres within a week of first going to a healthcare professional with signs of Rb. In 2023 this was 59%. Overall, 72% of children were diagnosed within the recommended two-week period, second only to 2022 when 73% of children were diagnosed within this time period.

Although Pathways to Diagnosis is designed to be a snapshot, or an indicator of trends in diagnosis in the UK, it is a key part of the resources we use to help CHECT achieve its aim of raising awareness of Rb in order to aid earlier diagnosis.

Public awareness

It's often parents or carers who spot the signs of Rb - whether that's a white eye seen in a family photo, a squint, or another symptom - public awareness is an important area of our work to help ensure a swift diagnosis. We use traditional and digital media to reach parents and other members of the public and raise awareness of Rb.

Media:

Previous research carried out by, or on behalf of, CHECT has shown that many people first hear about Rb after reading an article. We created press releases centering around prominent events of the year, including Rare Disease Day, World Retinoblastoma Awareness Week, Childhood Cancer Awareness Month and Christmas. We also have a freelance regional journalist who works throughout the UK to raise awareness of the stories of our CHECT Champions. During the reporting period we received over 130 mentions in the media, including 45 national pieces, giving 2.7 billion (+50% v previous year) people the opportunity to see or hear across all media outlets. Coverage included the BBC and ITV TV, radio, and digital, various national newspapers across the UK as well as coverage as far as America and Australia.

Page 9

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

Digital:

We continue to adapt the CHECT website to ensure that it is easy to navigate and contains relevant and useful information to visitors. The most visited pages remain our white eye and signs and symptoms and ts in the last reporting period are at a four-year high reaching over 153,000 people. New visitors and time spent on the website was at the highest ever levels

Social Media:

Social media is a key tool to raise awareness of Rb. In the period our Instagram followers increased by 17% and our Facebook followers by 2%. We reached over 500k people on Facebook, 200k people on Instagram and over 70k people on Twitter. Our TikTok channel has over 220 followers, our Instagram channel for CHECT TYA has over 230 followers and a LinkedIn channel has over 500 followers.

Ongoing communication:

Inclusivity

We have an Inclusivity Working Group to ensure that the charity is fully accessible and represents all those we support.

In the period outputs include:

Research

CHECT continues to support three ongoing projects:

Laboratory / Basic science

Professor Shin-Ichi Ohnuma: Evaluation of PRELP function using retinoblastoma samples.

Previous research by Professor Ohnuma has found that whilst PRELP protein is highly expressed in normal retinal tissues, it is not expressed in retinoblastoma. Preliminary data from cell cultures indicate that administration of PRELP to the established laboratory retinoblastoma cell lines inhibited cancer progression. Now, this team wants to confirm that these results have clinical application, by applying PRELP protein to the human retinoblastoma tissues and examining the effect on retinoblastoma development. The advantage of such an approach over some current methods is that only affected cells will be impacted by the treatment, with no expected toxicity to surrounding normal, unaffected retinal cells, thereby preserving more

Professor Seigel: A retinal organoid platform for retinoblastoma drug development.

One challenge in developing new treatments for retinoblastoma is to preserve vision by ensuring that Rb

Page 10

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

tumour cells are killed without damaging surrounding normal retina. For this project, we have a new approach for testing promising retinoblastoma drugs. We can coax adult human stem cells to represent -in-adish, we can disrupt the retina, like an Rb tumour might do in the human eye. This mixture of RB tumour cells with the retina-in-a-dish lets us use human cells to see whether our new drug treatments will kill Rb cells specifically without harming nearby retinal cells. This new method will be very useful for testing Rb treatments that we have developed with previous support from CHECT.

Clinical

Dr Zerrin Onadim: Eloise Patterson Project: Study of records held at The Royal London Hospital and Childhood Cancer Research Group on retinoblastoma patients Phase II.

This project was initially funded via a donation from the Greendale Foundation, inspired by a young adult who has previously had retinoblastoma, Eloise Patterson. Phase I (collection of clinical and mutation data and linking to Public Health England records) is now complete. This will provide complete information on type of Rb, type of mutation, treatment, follow-up data on second primary tumours and causes of any deaths.

We were delighted that the Greendale Foundation provided further support to allow for an additional phase to be delivered - Phase II (statistical analysis to estimate risks, which it is hoped could potentially lead to earlier diagnosis and treatment of these second cancers in current - and future - Rb populations), due to complete by the end of 2024.

Psychosocial

Dr Bob Phillips: Developing an evidence-based psycho-educational intervention for teenagers and young adults who have had retinoblastoma.

There is little guiding evidence about the specific challenges that teenagers who have had retinoblastoma face as they transition towards adulthood. Understanding the psycho-educational needs of teenagers and young adults as they transition is essential if we are to offer effective interventions to support them. This PhD studentship aims to develop an evidence-based intervention for teenagers and young adults with retinoblastoma that offers relevant, accessible, and effective psycho-educational support.

In 2023/24 we continued our objective of delivering an annual research award.

will start in July 2024.

Our thanks go to all members of our Scientific Advisory Committee, both lay and professional, who volunteer their time to make CHECT's research programme possible, and thus support our aim of improving the lives of everyone affected by retinoblastoma in the future.

Page 11

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

ACHIEVEMENT & PEFORMANCE

Fundraising

Fundraising Policy

CHECT does not use fundraising services or external professional fundraisers to undertake its fundraising activities. Additionally, no data is shared with or sold to any external agencies. The charity does not purchase external lists of potential individual donors or undertake direct mail appeals to such lists.

The charity issues a biannual newsletter and a monthly e-newsletter / blog (both of which can be easily unsubscribed from) that share information about the charitable work and fundraising activities undertaken.

The charity occasionally invites individuals to attend events but does not exert undue pressure to attend or to donate. It does not approach or pressure vulnerable people to support its work. A complaints policy is in place and is accessible on the charity's web site (www.chect.org.uk). The charity adheres to the Fundraising Code of Practice issued by the Fundraising Regulator.

Any fundraising events carried out on behalf of the charity that we are aware of are supported and monitored by the Fundraising Manager. Any marketing materials and approaches are checked t o e n s u r e that they comply with the Fundraising Code of Practice and details of income and expenditure are recorded by the Fundraising Manager. Income is acknowledged and grateful thanks are sent, typically with a letter and certificate.

Community and Events

We are incredibly grateful and always overwhelmed by the passion and dedication of our supporters, who go to such lengths to raise vital funds for us through the events and sponsored challenges they organise.

Highlights include:

Corporate Support

A huge thank you to the corporates who have supported us throughout the year.

Highlights include:

Page 12

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

Individual Giving

We are extremely grateful to all those who support us with a regular gift through a monthly pledge or Give As You Earn, as well as to those who so generously make a one-off donation to our charity.

We understand that the economic situation is difficult for many and are very grateful to all who donate to our charity.

Campaigns

month. The distance represented the approximate number of cases of Rb diagnosed each year. This took place h with £15,921 raised.

Over the Christmas period, our annual campaign raised over £12,000.

Trusts & Foundations

2023/24 was a challenging year, due to this area of fundraising being particularly hard hit by the cost-ofliving crisis immediately following the Covid-19 pandemic. Income from charitable trusts and foundations totaled just under £190k. We are extremely grateful to every trust and foundation which supported CHECT's work so generously during this period.

Cost of Living Fund, which was financed by the UK Government. The Community Organsations Cost of Living Fund awarded CHECT a grant of £65,420 towards our work providing direct specialist support to families affected by retinoblastoma. This grant was urgently needed at a very challenging time, and we are very grateful to the National Lottery Community Fund.

We would also like to thank the Greendale Foundation, the Eveson Trust, the February Foundation and the Jessica Mathers Trust for many years of very generous support.

We are enormously grateful to every one of the trusts and foundations that have so kindly and generously

In Memoriam

Trustees and staff would like to thank and offer sincere condolences to families and friends who have given

Page 13

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

in memory of a loved one during the year and are grateful to those who have kindly remembered us in their will.

With Thanks

Grandparents Ian and Heather demonstrated their generosity by donating £5,000 to CHECT following their kindness provides a vital lifeline for families like theirs who are experiencing the challenges of Rb.

treatment of his retinoblastoma. Our grandson now has a special eye but continues to excel at sport and academically. We commend you for the superb work th

We would like to express our gratitude to Ian and Heather for their support of CHECT. Their generous gift will play a pivotal role in ensuring we can continue to support every family in the UK who has been impacted by Rb.

Page 14

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

FINANCIAL REVIEW

Reserves Policy

CHECT maintains its reserves under two categories: (a) unrestricted (general) reserves, which are available for general use in pursuance of the charity's objectives, and (b) restricted reserves, which are for specifically earmarked purposes such as medical research or support to families belonging to a particular area.

The unrestricted funds of the Charity as of 31 March 2024 totalled £311,964. The Trustees have determined that the Charity should hold at least six months of running expenses in reserve. This figure represents the amount required to run the charity for six months excluding winding up costs and any special projects. Based on this calculation, the required value of reserves for the year 2024-25 is £247,947.

The reserves held as at 31 March 2024 represent 7 . 1 months of budgeted expenditure reducing to 6.1 months at the end of the coming financial year.

The Trustees review the Charity's reserves policy on a regular basis and no less than annually. The reserves position is reported at every board meeting.

Investment Policy

Funds surplus to immediate requirements are to be invested in interest bearing accounts without risk to the capital. Such accounts are to be those offered by institutions covered by the Financial Services Compensation Scheme (FSCS). No more than the amount covered by the FSCS is to be invested in any one institution.

Page 15

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

FINANCIAL PERFORMANCE

At the end of 2020/23 CHECT had deliberately built up a high level of unrestricted reserves as it was assumed that a difficult economic and fundraising environment would exist for both the 2023/24 and the 2024/25 period.

The objective was to ensure the delivery of the charities three pillars of activity;

Income was budgeted to fall as Trusts & Foundations would not be able to sustain their level of support. Additionally, it was anticipated that the long-term corporate partnership with Vision Express would come to an end.

Expenditure was to be carefully managed to ensure that this was focused on the delivery of the three pillars of activity alongside the pennies in the pound spent on charitable activity being protected and the ure (excluding research) was £46,600 in 2022/23, which reduced to £43,806 in 2023/2024 with the plan that this further reduces to £41,300 in 2024/25. This represents an 11% reduction in the period.

The charity planned a deficit budgeted 2023/24 knowing that the period was going to be a challenging financial climate.

The total incoming resources of the Charity were £449,484, which was a decrease of £197,110 on 202223's total income of £646,594. Total resources expended during the year decreased accordingly to £575,666 (2022-23: £604,841).

Overall, the Charity has recorded a d e f i c i t for the year of £126,182 compared to a s ur plu s of £41,753 in 2022-23. As of 31 March 2024, this has resulted in net assets decreasing from £444,946, at the preceding year end to £318,764. This comprises restricted funds of £6,800 (2022-23: £nil) and unrestricted funds of £311,964 (2022-23: £444,946)

Page 16

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

FUTURE PLANS

Our vision continues to be the leading charity in the United Kingdom dedicated to helping families and individuals affected by Rb.

Our mission is to lessen the impact of retinoblastoma by driving early diagnosis, funding research into prevention and treatment, and offering lifelong support now and for future generations.

Our focus over the coming period is to:

Support

The delivery of lifelong levels of support is the key focus of the charity using a support pathway that follows the key stages of the Rb journey research, pre-diagnosis, diagnosis, treatment, follow up, end of life.

We will provide our information, practical, social, financial, and emotional support at each of the above stages and continue the offer of both the direct and indirect (partnership) delivered services.

We will run events for the three main groups of members: families; teens and young adults; and older adults (Beyond Rb), across different regions of the UK.

We will work closely with partner organisations allowing more children and young people to experience events that can increase confidence and resilience.

We will continue to offer members memorable experiences through our special relationships with organisations such as the Free Kicks Foundation and Box4Kids.

in Autumn

Research

Research will continue to be a vital focus for us and our members. We were delighted to be able to make an award to Professor Venkata Yellapantula for his project " Prognostic stratification and early detection of relapsed retinoblastoma using aqueous humor based cfDNA screening" which commences in July 2024.

We will continue to manage and support the existing projects referenced earlier and continue our commitment to research via another call for projects and a further investment during 2024-25 and beyond.

Awareness

The raising of awareness around the signs and symptoms of Rb with both the public and the medical profession remains a vital function.

Page 17

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917)

diagnostic pathway to ensure that the right people have the right knowledge and information at the right time.

We are investing in digital media and are creating engaging content to aid in the raising of awareness.

Influence

We will continue to liaise with the different organisations involved in a child and family's journey to make sure the voice of our membership is heard and helps influence all, to deliver the best and most effective experience to all families.

Through partnership and alliance working we will look to use our position to positively influence policy to improve the pathways and associated levels of support for all those affected by Rb.

Page 18

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The Childhood Eye Cancer Trust (CHECT) ('the Charity') is a charitable company limited by guarantee ('the Company'), incorporated on 1 July 1987 and a registered charity. The Company was established under a Memorandum of Association, which established the objects and powers of the Company and is governed under its Articles of Association. The directors of the Company are also charity trustees for the purposes of charity law and are known as the board of trustees ('the Board'). The maximum number of trustees is 15.

The Company's Articles were amended in 2008 with regards to the number of terms Trustees may serve. In October 2022, the Articles were further amended to remove the requirement for Trustees to be re-elected periodically. This was because, noting the size and nature of the Charity, it is difficult to identify sufficient numbers of appropriately qualified and experienced candidates to fill such positions, with the process also being administratively cumbersome. Amendments to the Articles were also made to allow Society, General and Board of Trustee meetings to be held remotely.

Organisational structure

The Board meets six times a year and at the beginning of each meeting, the trustees are requested to declare any conflicts of interest. No conflicts of interest were declared during this financial year. The recruited to meet any needs or gaps identified. The Charity is a signatory to the NCVO's Good Governance Code for the voluntary and community sector.

To assist in the effectiveness and smooth running of the Charity the Board continues to resource two sub-committees to help oversee certain aspects of the Charity's work. Sub-committees are currently set up for: finance, risk and safeguarding and for research (Scientific Advisory Committee).

The day-to-day management of the Charity is delegated to the CEO, supported by the staff team. At the close of the year, staffing consisted of ten staff: a chief executive (four days per week); a head of finance & operations (four days per week); an operations manager (full time); two fundraising managers and one fundraising officer (two full time and one four days per week); a head of support services (four days per week) and two support workers - one in London (four days per week) and one in Birmingham (four days per week); and a communications manager (three days per week).

The Childhood Eye Cancer Trust is not affiliated with any other charitable organisation and has no related parties except as shown in the notes to the accounts. The Charity is a member of the Association of Medical Research Charities, the National Institute of Health Research, and other charities with similar aims to CHECT working within the field of eye health, childhood cancers, genetic disorders, and rare diseases.

Induction and training of new trustees

New trustees are provided with information about their role and responsibilities as recommended by the Charity Commission and the National Council for Voluntary Organisations (NCVO). This includes: the trustee role description and person specification relevant to the role, the Charity's confidentiality policy, and the eligibility requirements for becoming a trustee. They are also supplied with a copy of the Memorandum and Articles of Association, the strategic development plan and the chief executive's report and minutes from two previous board meetings.

Trustee roles are advertised on the CHECT website and on occasion, using external recruitment organisations. Enquiries are also occasionally received from members. A selection panel made up of the CEO, the Chair and another trustee or a member of the charity considers the application and the suitability of the applicant using agreed criteria identified on the person specification and the role description. The prospective trustee is then invited to observe a board meeting prior to appointment and standing for election which is voted on and approved by the Board.

Page 19

Induction meetings covering the background to current matters take place with the chief executive and key members of the staff team. Training on matters relevant to the role and responsibilities of trustees is encouraged and the Board subscribes to literature pertinent to good governance. All trustees are required to sign: a contract setting out their responsibilities; a confidentiality agreement; the conflict- o f - i n t e r e s t policy; and confirmation of their eligibility to serve as a director. They are also asked to undergo Disclosure and Barring Service (DBS) checks. The majority of trustees have personal experience of retinoblastoma and its impact but individuals with other key skills are also recruited to the Board to ensure an appropriate balance to meet the needs of the Charity.

Risk management

The trustees regularly assess the risks to the Charity and maintain a comprehensive risk register which includes plans to mitigate or manage the risks identified.

The risk register is reviewed by the Finance and Risk Committee at each of their meetings and in detail twice a year. Their discussions are reported at each Board Meeting, who in turn undertake a detailed annual review. The Chief Executive reviews on a monthly basis after which any concerns are discussed with the Chair of the Finance and Risk Committee.

In addition to the Treasurer and Finance and Risk Committee, there are nominated trustees with oversight and non-executive lead for Human Resources, Policies & Procedures, Safeguarding, Data Protection, Legal Matters, and Information Technology.

The trustees are satisfied that there are systems and arrangements in place to manage the risks identified as far as possible.

Safeguarding

As a charity we are committed to safeguarding our employees and all those who receive and give support.

Safeguarding children, young people, and adults, with a focus on those who are vulnerable and may be at risk is a priority for the Childhood Eye Cancer Trust. Our safeguarding focus helps our trustees and employees to remove, reduce and manage safeguarding risks for those we support and work with.

We review our safeguarding policy on an annual basis, have clear reporting processes, and follow up of any safeguarding concerns. All staff and trustees undertake annual safeguarding training. The delivery of our safeguarding obligations is person-centered, and outcomes focused, ensuring we are timely and proportionate in all our actions.

Page 20

STATEMENT OF TRUSTEES. RESPONSIBIUTIES The trustees (who are also the directors of Childhcod Eye Cancer Trust for the purpose5 of company lawy are responsibk for preparing the Trustees. Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (Untted Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Iretand." Company law requires the trustees to prepare financial statements for each financial year. These give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources. including the income and expendrture. of the charitable company for that period. In preparing those financial sLqtements. the trustees are required to select suitable accounting policies and then apply them consistently; observe the methods and principles in the Charty SORP. make judgements and estimates that are reasonable and prudent; and prepare the financial statements on the going concern basis unless it is inappropriate to presume thal the charitable company will continue in business. The trustees are responsible for keeping proper accounling records which disclose wrth reasonable accuracy at any time the financial position of the Gharitable company. and to enable them to ensure that the financial statements compty with the Companies Act 2006. They are also responsible for safeguarding the assels of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as the trustees are a4vare there Is no relevant audlt infomiation of which Ihe chaittable company's auditors are unaware,. and the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information. AUDITORS The auditors, Knox Cropper LLP, twi rtrappointed wrth a unanimous vote in favour by Trustees. This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies. Approved by order of the board of Trustees on 21st September 2024 and signed on its behalf by. lan Ellington - Trustee Page 21

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF CHILDHOOD EYE CANCER TRUST

Opinion

We have audited the financial statements of Childhood Eye Cancer Trust ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting

In our opinion the financial statements:

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions Relating to Going Concern

accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Page 22

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF CHILDHOOD EYE CANCER TRUST

Opinions on Other Matters Prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on Which we are Required to Report by Exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the Statement of Trustees Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Page 23

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF CHILDHOOD EYE CANCER TRUST

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our Report

Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for ou r audit work, for this report, or for the opinions we have formed.

Richard Billinghurst FCA (Senior Statutory Auditor) for and on behalf of Knox Cropper LLP 65 Leadenhall Street London EC3A 2AD

23/10/2024

Date: .............................................

Page 24

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING AN INCOME AND EXPENDITURE ACCOUNTI FOR THE YEAR ENDED 31 MARCH 2024 2023 Total funds Unrestrfctsd funds Restrlcted funds 2024 Total funds Notes INCOME AND ENDOWMENTS FROM: Donations and Legacies 279.695 157.414 437,109 639,710 Other Trading Activities 1.046 1,046 1,077 Investment Income 11,329 11,329 5,807 Total 292,070 157,414 449,484 646,594 EXPENDITURE ON: Raising Funds 128,670 128,670 169,066 Charitable activities Medical Research and Grant Making 104,834 5.000 109,834 61,392 Awareness Raising 113,002 113,002 107,647 Family Support and Information 57.217 145,614 202,831 252,206 Influencing 21.329 21,329 14,530 Total 425.052 150.614 575,666 604,841 NET INCOMEIIEXPENDITURE) (132.982) 6.800 (126,182) 41,753 RECONCILATION OF FUNDS Total Funds Brought Fon¥ard 403,193 TOTAL FUNDS CARRIED FORWARD 311,964 6.800 318,764 444,946 CONTINUING OPERATIONS All income and expenditure has arisen from continuing activities. Page 25

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 021439171 BALANCE SHEEf AT 31 MARCH 2024 2024 2023 Notes FIXED ASSETS Fixed Tangible Assets 14 465 CURRENT ASSETS Debtors 15 20,771 10,388 Cash at Bank and in Hand 478,558 628,831 499,329 639,219 CREDITORS Amounts Falling Due Wrthin One Year 16 (155,565) (188,017) NET CURRENT ASSErs 343,764 451,202 TOTAL ASSETS LESS CURRENT LIABILITIES 343,764 451,667 CREDITORS Amounts Falling Due After More Than One Year 17 {25.000) (6,721) NET ASSETS 318,764 444,946 FUNDS 20 Unrestricted funds 311.964 444,946 Restricted funds 6.800 TOTAL FUNDS 318.764 444,946 These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject lo the small companies, regime. The financial statements We￿ approved by the Board of Trustees on .. its behalf by.. lan Ell rustee Page 26

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2024

Notes 2024 2023
£ £
Cash flows from operating activities:
Cash Generated from Operations 22 (161,602) (2,487)
Finance Costs Paid - (577)
Net Cash (Used in)/Provided by Operating Activities (161,602) (3,064)
Cash Flows from Investing Activities:
Interest Received 11,329 5,807
Net Cash Provided by Investing Activities 11,329 5,807
Change in Cash and Cash Equivalents in
reporting period (150,273) 2,743
Cash and cash equivalents at beginning of
reporting period 628,831 626,088
Cash and cash equivalents at end of reporting
period 478,558 628,831

Page 27

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

1. Accounting Policies

Basis of preparing the financial statements

The financial statements of the Charity, which is a public benefit entity under FRS 102, have been prepared in Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard ting been prepared under the historical cost convention.

Going concern

cash flows for the following year are sufficient such that the Charity remains a going concern for the foreseeable future, being a period of at least 12 months from the date of approval of these financial statements. In making this judgement, the trustees and senior management team have considered future agreed funding and the anticipated impact of external factors on future funding and expenditure.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements in accordance with generally accepted accounting practice requires management to make estimates and judgements that affect the reported amounts of assets and liabilities at the reporting date and the reported amounts of revenues and expenses during the reporting period. The critical judgements and estimates are reflected in these accounting policies.

Income

All incoming resources are included in the Statement of Financial Activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income when appropriate:

Expenditure

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT that cannot be fully recovered, and is reported as part of the expenditure to which it relates:

Page 28

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

1. Accounting Policies continued

Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. The cost of minor additions or those costing below £250 are not capitalised. Depreciation is provided at rates calculated to write off the cost of each asset over its expected useful life, which in all cases is estimated at 4 years.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Debtors

Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid net of any trade discounts due.

Creditors

Creditors are recognised at their settlement amount, after allowing for any trade discounts due.

Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

Employee benefits

Short-term benefits are recognised as an expense in the period in which the service is received. Termination benefits are accounted for on an accrual basis and in line with FRS 102. The Charity operates a defined contribution pension scheme. Contributions are charged to the Statement of Financial Activities in the period to which they relate and are allocated between activities and funds based on the use of the resource i.e. where employees spend their time.

Taxation

The Charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the Charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged on a straight-line basis over the period of the lease.

Page 29

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

2. Donations and Legacies

Donations and Legacies
Unrestricted Restricted Total Total
funds funds 2024 2023
£ £ £ £
Grants
Grants from Trusts & Foundations 31,800 157,414 189,214 221,790
Government Grants -
31,800		 -
157,414		 -
189,214		 -
221,790
Donations:
General Donations 40,862 - 40,862 79,887
Standing Orders 21,770 - 21,770 21,782
In Memoriam 16,541 - 16,541 12,511
GAYE 4,644 - 4,644 5,549
Collecting Tins 2 - 2 1,149
Community Donations 333 - 333 2,434
Other Corporate Donations 36,092 - 36,092 101,654
London Marathon 16,525 - 16,525 39,075
Great North Run 6,852 - 6,852 9,747
Other Running Events and walks 5,531 - 5,531 66,251
Other events, Sporting Activities 98,743 - 98,743 72,881
and Community Fundraisers
247,895 - 247,895 412,920
Legacies - - - 5,000
Total Income from Donations 279,695 157,414 437,109 639,710
and Legacies

The Trustees would like to thank all the members and supporters who have contributed their time and effort to raising money for the Trust.

3. Other Trading Activities

2024 2023
Total Total
£ £
Christmas Cards 201 310
Merchandise Sales 845 767
1,046 1,077

Page 30

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

4. Investment Income

2024 2023
Total Total
£ £
Bank Interest 11,329 5,807
11,329 5,807

5. Raising Funds

2024 2023
Total Total
£ £
Raising Donations and Legacies
Staff Costs 73,138 99,822
Fundraising Costs 6,247 8,171
Support Costs 49,285 61,073
128,670 169,066

6. Charitable Activities

Grant
Funding of Support
Direct Costs Activities Costs (see 2024
(see note 7) (see note 8) note 9) Total
£ £ £ £
Medical Research and Grant Making 56,514 43,463 9,857 109,834
Awareness Raising 65,689 - 47,313 113,002
Family Support and Information 101,890 20,114 80,827 202,831
Influencing 11,472 - 9,857 21,329
235,565 63,577 147,854 446,996

7. Direct Costs of Charitable Activities

2024 2023
Total Total
£ £
Staff Costs 218,829 209,805
Newsletter Costs 3,324 3,075
Other Direct Costs 13,412 21,068
235,565 233,948

Page 31

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

8. Grants Payable

Grants Payable
2024 2023
Total Total
£ £
Medical Research and Grant Making 43,463 43,500
Family Support and Information 20,114 13,335
63,577 56,835

Page 32

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

9. Support Costs

Support costs are allocated to activities on the basis of staff time. Governance costs of £3,639 are included in support costs.

Raising Donations Total
and Legacies Medical Research and Family Support and Total Activities Activities
Grant Making Awareness Raising Information Influencing 2024 2023
£ £ £ £ £ £ £
Salaries 30,352 6,070 29,137 49,776 6,071 121,406 126,140
Premises Rent 4,211 842 4,043 6,906 842 16,844 11,409
Premises Costs 142 28 137 233 28 568 1,337
Repairs & Maintenance
168		 34 161 275 34 672 635
Communications and Stationery
4,236		 847 4,066 6,947 847 16,943 27,862
Meetings, Seminars and Staff
436		 87 420 716 87 1,746 1,666
Training
Travel and Subsistence
189		 37 181 309 38 754 906
Recruitment 6,226 1,247 5,977 10,211 1,245 24,906 21,395
Accountancy Fees 1,816 363 1,743 2,978 363 7,263 7,345
Sundries 404 84 388 663 81 1,620 3,410
Depreciation of Tangible Fixed
117		 21 112 192 23 465 472
Assets
Bank Charges 123 24 118 202 25 492 579
865 173 830 1,419 173 3,460 2,909
49,285 9,857 47,313 80,827 9,857 197,139 206,065

Page 33

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

10. Net Income (Expenditure)

2024 2023
Total Total
£ £
Auditors Remuneration 3,542 2,909
Depreciation
Owned Assets		 465 472
Non Audit Services 3,838 3,151
Net Income/(expenditure) as stated after charging/(crediting).

remuneration or other benefits for the year ended 31 March 2024 nor for the year ended 31 March 2023.

Trustees Expenses

During the current year £71 of expenses were reimbursed to the Trustees (2023: £129).

12. Staff Costs

Staff Costs
2024 2023
Total Total
£ £
Wages and Salaries 368,800 369,537
Social Security Costs 33,447 26,338
Other Pension Costs 11,126 7,401
Interim Fees Payable - 32,491
413,373 435,767

Included within wages and salaries are the direct costs of the interim CEO. The average monthly number of employees during the year was as follows:

2024 2023
Total Total
Average Number of Employees 10 10

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

2024 2023
Total Total
£ £
£60,000 - £70,000 1 -

Page 34

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

13. Comparatives For the Statement of Financial Activities

Unrestricted Restricted Total
Fund Funds Funds
£ £ £
INCOME AND ENDOWMENTS FROM
Donations and Legacies 553,401 86,309 639,710
Other Trading Activities 1,077 - 1,077
Investment Income 5,807 - 5,807
Total 560,285 86,309 646,594
EXPENDITURE ON
Raising Funds 169,066 - 169,066
Charitable Activities
Medical Research and Grant Making 61,392 - 61,392
Awareness Raising 107,647 - 107,647
Family Support and Information 163,356 88,850 252,206
Influencing 14,530 - 14,530
Total 515,991 88,850 604,841
NET INCOME /(EXPENDITURE) 44,294 (2,541) 41,753
RECONCILIATION OF FUNDS
Total Funds Brought Forward 400,652 2,541 403,193
TOTAL FUNDS CARRIED FORWARD 444,946 £- 444,946
14. Tangible Fixed Assets
Computer and Office
Equipment
£
COST
At 1 April 2023 and 31 March 2024 28,428
DEPRECIATION
At 1 April 2023 27,963
Charge for Year 465
At 31 March 2024 28,428
NET BOOK VALUE
At 31 March 2024 0
At 31 March 2023 465

Page 35

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

15. Debtors:

Debtors:
2024 2023
Total Total
£ £
Trade Debtors 509 123
Other Debtors 2,792 2,792
Prepayments and Accrued Income 17,470 7,473
20,771 10,388

16. Creditors: Amounts Falling Due Within One Year

2024 2023
Total Total
£ £
Trade Creditors 15,674 32,096
Pension Creditor 4,052 7,948
Deferred Income 23,489 14,668
Accruals 112,350 133,305
155,565 188,017

Included within Accruals is £108,418 for research grants awarded but expected to be drawn down within 12 months of the year end (2023: £79,936).

Deferred income relates to donations received in respect of future events, all of which is released in the following financial year.

17. Creditors: Amounts Falling Due After More Than One Year

2024 2023
Total Total
£ £
Accruals and Deferred Income 25,000 6,721

Accruals reflect grants awarded but not expected to be drawn down until more than 12 months after the current year end.

18. Leasing Agreements

Minimum lease payments under non-cancellable operating leases fall due as follows

2024 2023
Total Total
£ £
Within One year 5,125 -

In August 2023 a two-year lease was signed for office space and this lease includes a 6 month notice period for either party to end the agreement.

Page 36

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

19. Analysis of Net Assets Between Funds

Unrestricted Restricted 2024 2023
Fund Funds Total Funds Total Funds
£ £ £ £
Fixed Assets - - - 465
Current Assets 492,529 6,800 499,329 639,219
Current Liabilities (155,565) - (155,565) (188,017)
Long Term Liabilities (25,000) - (25,000) (6,721)
311,964 6,800 318,764 444,946

Included within restricted funds is the restricted Hobson grant which was received during the year but is restricted to activities in 2024/25.

20. Movement In Funds

Net
Movement in
At 1.4.23 Funds At 31.3.24
£ £ £
Unrestricted Funds
General Fund 444,946 (132,982) 311,964
Restricted Funds
Family Support - 6,800 6,800
TOTAL FUNDS 444,946 (126,182) 318,764

Net movement in funds, included in the above are as follows:

Incoming Resources Movement in
Resources Expended Funds
£ £ £
Unrestricted Funds
General Fund 292,070 (425,052) (132,982)
Restricted Funds
Family Support 152,414 (145,614) 6,800
Research 5,000 (5,000) -
TOTAL FUNDS 449,484 (575,666) (126,182)

Page 37

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

20. Movement In Funds - continued

Movement In Funds - continued
Comparatives for Movement in Funds Net
Movement in
At 1.4.22 Funds At 31.3.23
Unrestricted Funds £ £ £
General Fund 400,652 44,294 444,946
Restricted Funds
Family Support 2,541 (2,541) -
TOTAL FUNDS 403,193 £41,753 £444,946

Comparative net movement in funds, included in the above are as follows:

Incoming Resources Movement in
Resources Expended Funds
£ £ £
Unrestricted Funds
General Fund 560,285 (515,991) 44,294
Restricted Funds
Family Support 86,309 (88,850) (2,541)
TOTAL FUNDS 646,594 (604,841) 41,753

Purposes of Restricted Funds

Available for research into various projects that promote the objects of the Charity

Research Available for research into various projects that promote the objects of the Charity Family Support To provide support and information to families and individuals affected by retinoblastoma. Kent Travel

A fund to provide eligible families living in Kent with one-off travel grants for financial assistance with travel to UK clinics.

Page 38

CHILDHOOD EYE CANCER TRUST (REGISTERED NUMBER: 02143917) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024

21. Related Party Disclosures

There were no related party transactions for the year ended 31 March 2024 or 31 March 2023.

22. Reconciliation of Net (Expenditure)/Income To Net Cash Flow From Operating Activities

Operating Activities
2024 2023
Total Total
£ £
Net (Expenditure)/Income for the reporting period (as per the (126,182) 41,752
Statement of Financial Activities)
Adjustments for:
Depreciation Charges 465 472
Interest Received (11,329) (5,807)
Finance Costs - 580
Decrease in Debtors (10,383) 125
(Decrease) in Creditors (14,173) (39,609)
Net Cash (used in)/provided by operations (161,602) (2,487)

23. Analysis Of Changes In Net Funds

At 1.4.23 Cash Flow At 31.3.24
Net Cash £ £ £
Cash at Bank 628,831 (150,273) 478,558
Total 628,831 (150,273) 478,558

24. Capital Commitments

At the year end the Trust Board had no capital commitments (2023: £nil).

Page 39